Breaking News

Sterling Pharma Solutions Acquires ADC Biotechnology

Will establish a center of excellence for bioconjugation and ADC development and manufacturing services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has acquired ADC Biotechnology, a UK-based bioconjugation development services business specializing in antibody drug conjugates (ADCs).   This follows an announcement by Sterling in December of a strategic investment into the ADC Bio business, with a view to acquisition in 2021.   The North Wales facility will rebrand to become part of the Sterling Pharma Solutions international network. Together the t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters